يعرض 1 - 8 نتائج من 8 نتيجة بحث عن '"Aymon, Romain"', وقت الاستعلام: 1.66s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: HUS Internal Medicine and Rehabilitation, Department of Medicine, Clinicum

    وصف الملف: application/pdf

    العلاقة: The JAK-pot study has received unrestricted research grant from: AbbVie, Galapagos, Pfizer and Eli Lilly. BIOREG, the Austrian registry for biologicals, biosimilars and tsDMARDs in the treatment of inflammatory rheumatic diseases, is in close partnership with the Austrian Society for Rheumatology and Rehabilitation (OGR) and is supported by an unrestricted educational grant from AbbVie, Amgen, Eli Lilly, Fresenius-Kabi, Gilead, Janssen-Cilag, MSD, Pfizer, Sandoz, UCB. Clinical work in Czech Republic was partially supported by the project from the Ministry of Health for conceptual development of research organisation MZ00023728023728 (Institute of Rheumatology). BIOBADASER has received funding from Fundacion Espanola de Reumatologia, the Spanish Medicines and Health Products Agency (Agencia Espanola del Medicamento y Productos Sanitarios) and equal grants from pharmaceutical companies (AbbVie, BMS, Celltrion, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Regeneron, Roche, Samsung, Schering-Plough and UCB). BioRx. si has received funding for clinical research paid to Drustvo za razvoj revmatologije from AbbVie, Roche, Medis, MSD, Biogen, Amgen, Sanofi, Celgene and Pfizer. The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) is funded by a grant from the British Society for Rheumatology (BSR). The BSR currently receives funding from AbbVie, Amgen, Celltrion Healthcare, Eli Lilly, Galapagos, Pfizer, Samsung Bioepis and Sanofi and in the past Hospira, MSD, Roche, Sandoz, SOBI and UCB. This income finances a wholly separate contract between the BSR and The University of Manchester to host the BSRBR-RA. All decisions concerning study design, data capture, analyses, interpretation and publication are made autonomously of any industrial contribution. Members of the BSRBR-RA University of Manchester team, BSR trustees, committee members and staff complete an annual declaration in relation to conflicts of interest. All relevant information regarding serious adverse events outlined in the manuscript have been reported to the appropriate pharmaceutical company as per the contractual agreements/ standard operating procedures. DANBIO was partially supported by public and private funding (AbbVie, Biogen, Bristol Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB). NOR-DMARD has been supported with research funding to Diakonhjemmet Hospital from AbbVie, Amgen, BMS, MSD, Novartis, Pfizer and UCB. The German RABBIT registry is currently supported by a joint, unconditional grant from AbbVie, Amgen, BMS, Celltrion, Fresenius Kabi, Galapagos, Hexal, Lilly, MSD, Pfizer, Samsung Bioepis, Sanofi Aventis, VIATRIS SANTE and UCB, and previously by Roche. REUMA. PT is supported by unrestricted grants from AbbVie, Biogen, Celgene, MSD, Roche, Sanofi and Pfizer. ROB-FIN is funded by AbbVie, Hospira, BMS, MSD, Pfizer, Roche and UCB. The Romanian Registry of Rheumatic Diseases (RRBR) uses unrestricted grants from AbbVie, Pfizer, Eli Lilly, Ewopharma, Nopvartis MSD, Roche, UCB, and BMS. Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) database is sponsored by public and industrial support (http://scqm.ch/enTest/ sponsoren/).; Aymon , R , Mongin , D , Bergstra , S A , Choquette , D , Codreanu , C , De Cock , D , Dreyer , L , Elkayam , O , Huschek , D , Hyrich , K L , Iannone , F , Inanc , N , Kearsley-Fleet , L , Koca , S S , Kvien , T K , Leeb , B F , Lukina , G , Nordström , D C , Pavelka , K , Pombo-Suarez , M , Rodrigues , A , Rotar , Z , Strangfeld , A , Verschueren , P , Westermann , R , Zavada , J , Courvoisier , D S , Finckh , A & Lauper , K 2024 , ' Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study) ' , Annals of the Rheumatic Diseases , vol. 83 , no. 4 , pp. 421-428 . https://doi.org/10.1136/ard-2023-224670Test; http://hdl.handle.net/10138/574261Test; aef68eeb-ba11-470f-b986-628e05a21385; 001119185000001

  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية